clinical trial · NCT04809233

Expanded Access to Tipifarnib

$KURA →·—·available

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)Tipifarnib

brief summary

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.

started

—

primary completion

—

completion

—

last updated

Jun 4, 2025

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol